Catalyst Pharmaceuticals (CPRX) Capital Expenditures (2011 - 2026)

Catalyst Pharmaceuticals' Capital Expenditures history runs 13 years deep, the most recent figure standing at $27000.0 for Q1 2026.

• Quarterly Capital Expenditures changed N/A year-over-year to $27000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $85000.0 (down 76.19% YoY) and the FY2025 annual result came in at $58000.0, down 89.57% from the prior year.
• Capital Expenditures was $27000.0 for Q1 2026 at Catalyst Pharmaceuticals, down from $32000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $259000.0 in Q3 2024 and bottomed at $10000.0 in Q2 2024.
• A 4-year average of $87200.0 and a median of $69000.0 in 2023 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2024 — Capital Expenditures jumped 304.69% — and 2025, when it slumped 63.64%.
• Catalyst Pharmaceuticals' Capital Expenditures stood at $93000.0 in 2023, then dropped by 5.38% to $88000.0 in 2024, then slumped by 63.64% to $32000.0 in 2025, then fell by 15.62% to $27000.0 in 2026.
• Business Quant data shows CPRX's Capital Expenditures at $27000.0 in Q1 2026, $32000.0 in Q4 2025, and $26000.0 in Q2 2025.